BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Datavant to Acquire Aetion, Expanding Into End-to-End Real-World Evidence Analytics for Life Sciences

by BiopharmaTrend   •   May 26, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Startups & Deals   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Datavant has announced its acquisition of Aetion, a real-world evidence (RWE) platform used by regulators and biopharma companies to assess drug effectiveness and safety. The combined platform is expected to offer an end-to-end solution for discovering, linking, curating, and analyzing real-world data at scale, building on Datavant’s tokenization and connectivity infrastructure and Aetion’s regulatory-grade analytics suite.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

Datavant, previously positioned as a neutral health data connector, will now directly compete with platforms using its own infrastructure. Brigham Hyde, CEO of Atropos Health, likened the acquisition to the ambient AI boom, referencing companies like Abridge (now valued at $2.75 billion) as examples of best-in-class emergence. He also commented:

"We applaud the direction here. I think we're just at the beginning. I think Datavant realizes that and is voting behind it.
What does this mean for the real-world data and healthcare data ecosystem for Datavant to leave their neutral position and begin competing with their own network and companies that have trusted and built with them for years? Will that lead to a shift in those networks and what tokens are used for de-identification? That's an unknown, but that's the question in everybody's mind."

The acquisition integrates Aetion’s Evidence Platform and new Activate module (which supports code and no-code workflows for biostatistics and epidemiology) with Datavant Connect, which leverages AWS Clean Rooms for privacy-preserving data access. Post-close, the joint ecosystem will span over 300 data partners, with enhanced tools for evidence planning, data discovery, and regulatory use cases across biopharma, payers, and health systems.

Aetion’s analytics will now be embedded within Datavant’s broader infrastructure, enabling users to move from data exchange to real-time insights across the drug lifecycle. The Aetion platform is also now available via AWS Marketplace, further aligning the ecosystem with cloud-first deployment and interoperability models.

Topics: Startups & Deals   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.